

NYRx BLTG Program Update

What Pharmacy Providers and Prescribers Need to Know

Flovent® and **Advair®** products continue to be included in the Brand Less Than Generic Program (BLTG). However, due to recent changes announced by the manufacturer including the discontinuation of Flovent® and the decreased production of Advair®, effective **December 21, 2023**, the NYRx Medicaid Pharmacy Program will allow for the generics to these products to adjudicate without prior authorization. If a pharmacy is unable to obtain Flovent® or Advair® from their wholesaler and the member needs the medication, they may submit for the generic product.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require “Dispense as Written” (DAW) or “Brand Medically Necessary” on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of “1”; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exceptions to this are DAW code “1” and “Brand Medically Necessary” on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
Advair Diskus®	Glumetza®	Renvela® tablet
Advair HFA®	Kazano®	Restasis®
Alphagan P® 0.15%	Kitabis® Pak	Retin-A® cream
Amitiza®	Kombiglyze® XR	Ritalin LA®
Apriso®	Lialda®	Spiriva® HandiHaler®
Azopt™	Nesina®	Symbicort®
Bethkis®	Nexavar®	Tegretol® suspension
Cellcept® suspension	NuvaRing®	Tegretol® XR
Combigan®	Onglyza®	Trileptal® suspension
Copaxone® 20mg SQ	Oseni®	Vascepa®
Daytrana®	Pennsaid® pump	Ventolin® HFA
Depakote® Sprinkle	Pentasa®	Vyvanse® capsule
Dexilant®	Pradaxa®	Vyvanse® chewable tablet
Dymista®	Protonix® suspension	Xopenex HFA®
Epipen	Pylera®	Zegerid® Rx
Epipen JR	Rapamune® solution	
Flovent® HFA	Renvela® powder pack	

* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Pharmacy Program Preferred Drug List](#)

Contact Information

The NYRx Education & Outreach Call Center is available at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.